Carthera Taps Dr. Ørn R. Stuge as Chairman Amid Phase III Readiness
- Orsco Lifesciences AG
- Sep 17, 2023
- 1 min read
Paris, France — September 18, 2023. Carthera, a spin-off from Sorbonne University pioneering the SonoCloud® ultrasound implant technology to temporarily open the blood–brain barrier for enhanced drug delivery, has appointed Dr. Ørn R. Stuge, MD, MBA as Chairman of its Board of Directors. The move comes as Carthera ramps up its pivotal Phase III trial for the SonoCloud-9 device targeting recurrent glioblastoma and prepares for eventual market launch. (Carthera)
“We are thrilled to welcome Dr. Stuge, a trusted senior advisor and well‑versed medical‑device expert, to head up our board of directors,” said Frederic Sottilini, CEO of Carthera. “He has participated in the development of several businesses, some of which he successfully sold or listed, including a unicorn. Dr. Stuge will help refine our strategy and enable accelerated growth.”
Dr. Stuge brings 30+ years of executive leadership—from leading structural heart innovations at Medtronic and earlier senior roles at Abbott to CEO of Medinor A/S—paired with an IMD MBA education in Lausanne.
Governance note: As Chairman of Carthera, Ørn R. Stuge, MD, MBA provides expert med-tech governance and global strategic leadership drawn from his experience across Orsco Lifesciences and multiple successful ventures.
Comments